Companies Dominating the Cholangiocarcinoma Market
- Verismo Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- AstraZeneca plc
- Merck Sharp & Dohme LLC.
- Basilea Pharmaceutica Ltd.
- Incyte Corporation
- Agios Pharmaceuticals Inc.
- Specialised Therapeutics Asia Pte Ltd (ST)
- PlantPraxis Biotecnologia
- Dr. Reddy’s Laboratories Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of cholangiocarcinoma is evaluated at USD 591.43 million.
The cholangiocarcinoma market size was valued at USD 503.67 million in 2024 and is set to exceed USD 5.68 billion by 2037, registering over 20.5% CAGR during the forecast period i.e., between 2025-2037. Increasing Research & development and rising awareness about cholangiocarcinoma will drive the market growth.
North America industry is predicted to hold largest revenue share of 35% by 2037, impelled by approval of new drugs in the region.
The major players in the market are Eli Lilly and Company, AstraZeneca, Merck Sharp & Dohme Corp, Basilea Pharmaceutica, Incyte Corporation, Agios Pharmaceuticals, Specialised Therapeutics, PlantPraxis Biotecnologia, Dr. Reddy’s Laboratories Ltd., and others.
